Choosing a Cannabis Product Based on Its Potency? Be Wary of Misrepresentation

With the rise of legal cannabis markets, customers rely heavily on product labels to understand the potency and potential effects of what they’re consuming, particularly regarding tetrahydrocannabinol (THC) and cannabidiol (CBD) content. However, a recent study published in JAMA Network Open titled Label Accuracy of Legal Oral Cannabis Oil Products in Ontario, Canada revealed a troubling issue: many cannabis products on the market do not match their labeled potency claims. This discrepancy poses risks for both medical and recreational users who depend on accurate labeling for safe and effective consumption.

Why is Accurate Labeling Crucial in the Cannabis Industry?

The potency of a cannabis product—especially the concentration of THC and CBD—directly influences its effects. Medical patients, for example, depend on precise dosages to manage symptoms effectively, while recreational users want to tailor their consumption to achieve desired effects without overindulgence. In the case of THC, both consumers can face uncomfortable euphoria with inaccurate labeling.

The study revealed a significant issue with potency misrepresentation: Out of 30 products tested, 40% of the products tested had THC levels outside of the federally permitted 15% variability limit, and 10% were outside the limit for CBD content. This means that a considerable portion of products contain either more or less active compounds than their labels suggest.

For instance, the study highlighted one product labeled as having 5 mg/g of CBD but found to contain a startling 26 mg/g after laboratory testing. Furthermore, 7 out of 16 THC products that had 2.5mg of THC or greater contained lower amounts of the cannabinoid by more than 15%. Mislabeling like this can make it challenging for patients to gauge how much of a product they should take, leading to potentially ineffective dosages. With many patients relying on cannabis for critical conditions such as epilepsy, it is crucial that the products have accurate labeling for consistent dosage.

How Is This Possible in a Regulated Industry?

With strict labeling regulations in place since the legalization in 2018 of recreational cannabis in Canada, many wonder how potency inaccuracies continue to persist in the legal cannabis market. After all, legal markets should guarantee quality control, right?

The study suggests otherwise. Out of the 30 products tested in Ontario, nearly half of the higher-potency items had THC levels more than 15% lower than advertised. Additionally, 33.3% of the products had discrepancies between their online product descriptions and physical labels. Even more concerning, 16.7% of products had conflicting information within their own labels—where active and total cannabinoid concentrations did not match as they should.

These inaccuracies persist partly due to gaps in enforcement. Regulations can set standards, but without rigorous testing and enforcement, those standards can be easily missed.  While federal regulations set clear standards, the complexity of production processes and lack of stringent oversight at various stages may lead to discrepancies that are not caught until the product reaches the consumer. This highlights a crucial flaw in the industry’s quality control systems.

Why Misrepresentation is Dangerous

For consumers—especially medical users—potency misrepresentation can lead to severe consequences. Medical patients may over or under-dose on their medication, resulting in ineffective treatment or exacerbation of symptoms. For instance, if a product contains far less THC than advertised, patients might not experience the pain relief or symptom control they were expecting.

Recreational users are also at risk. While the study found no instances of cannabis oils containing more THC than labeled at levels that would cause adverse psychoactive effects, underdosing can still lead to consequences. For example, users expecting a certain level of euphoria may consume more to compensate, increasing their chances of impaired judgment or overconsumption over time.

Beyond individual health risks, the widespread issue of potency misrepresentation erodes consumer trust in the legal cannabis market. Many turn to legal sources because they believe that regulatory oversight ensures safety and accuracy. When that trust is broken, it not only damages the reputation of legitimate cannabis businesses but also drives consumers back to the illicit market, where quality control is even less reliable.

The Need for Greater Oversight

The study on cannabis oil products in Ontario serves as a wake-up call for consumers and industry stakeholders alike. While regulations aim to ensure product safety and consistency, the reality is that many cannabis products still fall short.

As the study points out, “a legal market is not an assurance of accurate labeling.” There is an urgent need for stricter enforcement of existing regulations, more frequent product testing, and harsher penalties for companies that fail to meet labeling standards. Labeling accuracy is more than a regulatory issue; it’s a consumer safety issue. Consumers depend on accurate information to make informed decisions about their health and well-being. Ensuring that what’s on the label matches what’s in the product is fundamental to protecting public health.

As the industry matures, it must focus on improving the accuracy of product labels through stricter oversight and quality control. By investing in better testing practices, conducting more frequent inspections, and implementing harsher penalties for non-compliance, the industry can craft a new standard. Until then, consumers need to be cautious and informed, understanding that what’s on the label may not always reflect what’s in the product.